Cargando…

Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives

SIMPLE SUMMARY: Contrast imaging techniques play a pivotal role in the diagnosis and management of Intrahepatic cholangiocarcinoma (iCCA). There is an increasing interest in the specific imaging features which can predict tumor behavior or histologic subtypes. ABSTRACT: Intrahepatic cholangiocarcino...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerrito, Lucia, Ainora, Maria Elena, Borriello, Raffaele, Piccirilli, Giulia, Garcovich, Matteo, Riccardi, Laura, Pompili, Maurizio, Gasbarrini, Antonio, Zocco, Maria Assunta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341250/
https://www.ncbi.nlm.nih.gov/pubmed/37444503
http://dx.doi.org/10.3390/cancers15133393
_version_ 1785072217898352640
author Cerrito, Lucia
Ainora, Maria Elena
Borriello, Raffaele
Piccirilli, Giulia
Garcovich, Matteo
Riccardi, Laura
Pompili, Maurizio
Gasbarrini, Antonio
Zocco, Maria Assunta
author_facet Cerrito, Lucia
Ainora, Maria Elena
Borriello, Raffaele
Piccirilli, Giulia
Garcovich, Matteo
Riccardi, Laura
Pompili, Maurizio
Gasbarrini, Antonio
Zocco, Maria Assunta
author_sort Cerrito, Lucia
collection PubMed
description SIMPLE SUMMARY: Contrast imaging techniques play a pivotal role in the diagnosis and management of Intrahepatic cholangiocarcinoma (iCCA). There is an increasing interest in the specific imaging features which can predict tumor behavior or histologic subtypes. ABSTRACT: Intrahepatic cholangiocarcinoma (iCCA) represents the second most common liver cancer after hepatocellular carcinoma, accounting for 15% of primary liver neoplasms. Its incidence and mortality rate have been rising during the last years, and total new cases are expected to increase up to 10-fold during the next two or three decades. Considering iCCA’s poor prognosis and rapid spread, early diagnosis is still a crucial issue and can be very challenging due to the heterogeneity of tumor presentation at imaging exams and the need to assess a correct differential diagnosis with other liver lesions. Abdominal contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) plays an irreplaceable role in the evaluation of liver masses. iCCA’s most typical imaging patterns are well-described, but atypical features are not uncommon at both CT and MRI; on the other hand, contrast-enhanced ultrasound (CEUS) has shown a great diagnostic value, with the interesting advantage of lower costs and no renal toxicity, but there is still no agreement regarding the most accurate contrastographic patterns for iCCA detection. Besides diagnostic accuracy, all these imaging techniques play a pivotal role in the choice of the therapeutic approach and eligibility for surgery, and there is an increasing interest in the specific imaging features which can predict tumor behavior or histologic subtypes. Further prognostic information may also be provided by the extraction of quantitative data through radiomic analysis, creating prognostic multi-parametric models, including clinical and serological parameters. In this review, we aim to summarize the role of contrast-enhanced imaging in the diagnosis and management of iCCA, from the actual issues in the differential diagnosis of liver masses to the newest prognostic implications.
format Online
Article
Text
id pubmed-10341250
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103412502023-07-14 Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives Cerrito, Lucia Ainora, Maria Elena Borriello, Raffaele Piccirilli, Giulia Garcovich, Matteo Riccardi, Laura Pompili, Maurizio Gasbarrini, Antonio Zocco, Maria Assunta Cancers (Basel) Review SIMPLE SUMMARY: Contrast imaging techniques play a pivotal role in the diagnosis and management of Intrahepatic cholangiocarcinoma (iCCA). There is an increasing interest in the specific imaging features which can predict tumor behavior or histologic subtypes. ABSTRACT: Intrahepatic cholangiocarcinoma (iCCA) represents the second most common liver cancer after hepatocellular carcinoma, accounting for 15% of primary liver neoplasms. Its incidence and mortality rate have been rising during the last years, and total new cases are expected to increase up to 10-fold during the next two or three decades. Considering iCCA’s poor prognosis and rapid spread, early diagnosis is still a crucial issue and can be very challenging due to the heterogeneity of tumor presentation at imaging exams and the need to assess a correct differential diagnosis with other liver lesions. Abdominal contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) plays an irreplaceable role in the evaluation of liver masses. iCCA’s most typical imaging patterns are well-described, but atypical features are not uncommon at both CT and MRI; on the other hand, contrast-enhanced ultrasound (CEUS) has shown a great diagnostic value, with the interesting advantage of lower costs and no renal toxicity, but there is still no agreement regarding the most accurate contrastographic patterns for iCCA detection. Besides diagnostic accuracy, all these imaging techniques play a pivotal role in the choice of the therapeutic approach and eligibility for surgery, and there is an increasing interest in the specific imaging features which can predict tumor behavior or histologic subtypes. Further prognostic information may also be provided by the extraction of quantitative data through radiomic analysis, creating prognostic multi-parametric models, including clinical and serological parameters. In this review, we aim to summarize the role of contrast-enhanced imaging in the diagnosis and management of iCCA, from the actual issues in the differential diagnosis of liver masses to the newest prognostic implications. MDPI 2023-06-28 /pmc/articles/PMC10341250/ /pubmed/37444503 http://dx.doi.org/10.3390/cancers15133393 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cerrito, Lucia
Ainora, Maria Elena
Borriello, Raffaele
Piccirilli, Giulia
Garcovich, Matteo
Riccardi, Laura
Pompili, Maurizio
Gasbarrini, Antonio
Zocco, Maria Assunta
Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives
title Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives
title_full Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives
title_fullStr Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives
title_full_unstemmed Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives
title_short Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives
title_sort contrast-enhanced imaging in the management of intrahepatic cholangiocarcinoma: state of art and future perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341250/
https://www.ncbi.nlm.nih.gov/pubmed/37444503
http://dx.doi.org/10.3390/cancers15133393
work_keys_str_mv AT cerritolucia contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives
AT ainoramariaelena contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives
AT borrielloraffaele contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives
AT piccirilligiulia contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives
AT garcovichmatteo contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives
AT riccardilaura contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives
AT pompilimaurizio contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives
AT gasbarriniantonio contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives
AT zoccomariaassunta contrastenhancedimaginginthemanagementofintrahepaticcholangiocarcinomastateofartandfutureperspectives